Related Experiment Video
Updated: Mar 16, 2026

In Vitro and In Vivo Models to Study Corneal Endothelial-mesenchymal Transition
Published on: August 20, 2016
New drug delivery system for corneal administration of mitomycin-C
Francisco Irochima Pinheiro1, Irami Araújo-Filho1, Amalia Cinthia Meneses do Rego1
1From the Graduate Program in Biotechnology (Pinheiro, Araújo-Filho, Rego, Azevedo), Potiguar University, the Laboratory of Dispersed Systems (Tabosa do Egito), Federal University of Rio Grande do Norte, Natal-RN, the Division of Uveitis, Brazilian Center for Visual Sciences (Oréfice), Belo Horizonte-MG, Ophthalmos S/A (Lima Filho), and the Department of Ophthalmology (Lima Filho), Federal University of São Paulo (USP), São Paulo, Brazil.
Purpose:
To develop a new corneal release system to deliver optimum amounts of mitomycin-C (MMC) during the perioperative period of photorefractive keratectomy (PRK).
Setting:
Ophthalmos S/A, São Paulo, Brazil.
Design:
Experimental study.
Methods:
An in vitro experimental design was developed for studying a new MMC delivery system at a drug concentration of 0.02%. Whatman sterile filter paper disks with a diameter of 8.0 mm were impregnated with MMC solution. After drying, the disks were placed on agar plates seeded with Staphylococcus epidermidis; this was followed by instillation of a drop of sterile water. After 1 minute, the disks were removed and the plates were incubated for 48 hours at 35°C. The mean volume of the drops delivered from regular eyedrop bottles was determined, and the inhibition zone (in millimeters) was correlated with the amount of MMC loaded onto the disks.
Results:
Analysis of the inhibition zones produced by MMC indicated that 16 μg was the optimum dose to be incorporated in the disks. The mean volume of a drop delivered from eyedrop bottles was 37.7 μL. One minute after the application of a single drop of a balanced salt solution, the system released an adequate concentration of MMC for PRK.
Conclusion:
A new delivery system for MMC was successfully developed for application during photorefractive keratectomy.
Financial Disclosure:
Dr. de Souza Lima Filho is the managing director of Ophtalmos S/A. Drs. de Souza Lima Filho, Irochima Pinheiro, and Oréfice have exclusive rights to intellectual property of this invention secured by a patent application filed with the Instituto Nacional da Propriedade Industrial.
More Related Videos
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
07:29Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
Published on: November 12, 2015
Related Concept Videos
Ophthalmic Drug Delivery Systems
Modified-Release Drug Delivery Systems: Site-Targeted
Transdermal Drug Delivery Systems
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Rate-Programmed I